Update: Amendments to the Medical Devices Regulations came into force on January 3, 2024 substantially as proposed: Regulations Amending the Medical Devices Regulations (Medical Devices for an Urgent Public Health Need) (see also Health Canada’s notice and guidance).
Health Canada has proposed amendments to the Medical Devices Regulations (Regulations) that would expand the regulatory framework for COVID-19 medical devices to apply to future public health emergencies (see Proposed changes to the Medical Devices Regulations to address future public health emergencies: Notice).
Under the proposed amendments, Part 1.1 of the Regulations would no longer be specific to COVID-19 medical devices. Instead, Part 1.1 would apply to medical devices that have an urgent public health need (UPHN) in relation to a medical condition for which there is a public health emergency. The proposed amendments would also:
- allow the Minister of Health (Minister) to add a medical condition to the List of Medical Devices for an Urgent Public Health Need in Relation to COVID-19 where specific criteria are met;
- allow for the inclusion of additional medical conditions on the List of Medical Devices for Expanded Use in Relation to COVID-19 (and any other relevant provisions) when necessary; and
- allow the Minister to issue an authorization even if the UPHN status of a device changes after a manufacturer submits an application for authorization in respect of that device.
The proposed amendments also address amendments to authorizations, requirements to inform the Minister of foreign authorization/licence revocation or suspension, and fee requirements and exemptions. Health Canada’s consultation on the proposed amendments closed on April 13, 2023.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Federal Court of Appeal dismisses appeal of SPRAVATO “innovative drug” decision
On November 10, 2021, the Minister of Health refused to reassess its decision that Janssen’s esketamine hydrochloride product (SPRAVATO) was not an “innovative drug” and therefore not entitled to data...Read More -
CIPO will not issue patents on July 9 or July 16
The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More